Should I buy or sell Brightpoint stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brightpoint in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CELL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CELL, but not buy additional shares or sell existing shares. View CELL analyst ratings or view top-rated stocks .

What is Brightpoint's stock price target for 2024?

3 brokerages have issued 12-month target prices for Brightpoint's shares. Their CELL share price targets range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $1.50 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View analysts price targets for CELL or view top-rated stocks among Wall Street analysts .

What other stocks do shareholders of Brightpoint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brightpoint investors own include (VMED) (VMED) , TiVo (TIVO) , RTX (RTX) , Broadcom (AVGO) .

NASDAQ:CELL

Brightpoint (CELL) Stock Price, News & Analysis

→ The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad)

Free CELL Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.00
▼
$1.00
50-Day Range: $2.14
▼
$2.31
52-Week Range: N/A

Volume: N/A
Average Volume: 676,796 shs
Market Capitalization: $99.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Stock Analysis

Get Brightpoint alerts:

Brightpoint MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 50.3% Upside
$1.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.03) to ($0.62) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Medical Sector

779th out of 918 stocks

Analytical Instruments Industry

24th out of 26 stocks

3.0

Analyst's Opinion

Consensus Rating
Brightpoint has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Brightpoint has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for CELL.

0.0

Dividend Strength

Dividend Yield
Brightpoint does not currently pay a dividend.
Dividend Growth
Brightpoint does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CELL.

0.6

News and Social Media Coverage

Search Interest
Only 3 people have searched for CELL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
1 people have added Brightpoint to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Brightpoint insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.60% of the stock of Brightpoint is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
58.39% of the stock of Brightpoint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Brightpoint are expected to grow in the coming year, from ($1.03) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Brightpoint is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Brightpoint is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Brightpoint has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Brightpoint Stock (NASDAQ:CELL)

Brightpoint, Inc.(BrightPoint) is engaged in providing device lifecycle services to the wireless industry. The Company provides customized logistic services, including demand planning, procurement, inventory management, software loading, kitting and customized packaging, fulfillment, credit services, receivables management, call center services, activation services, Website hosting, e-fulfillment solutions, repair, refurbish and recycle services, reverse logistics, transportation management and other services within the global wireless industry. The Company’s has three geographic segments, the Americas, EMEA and Asia-Pacific. Its customers include mobile network operators, mobile virtual network operators (MVNOs), resellers, retailers and wireless equipment manufacturers. In March 2011, the Company acquired the business and assets of C20 Mobile Pte. Ltd. and C20 Corporation Pte. Ltd. In October 2012, Ingram Micro Inc acquired Brightpoint.

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

CELL Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive CELL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brightpoint and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:CELL
CUSIP: N/A
CIK: 918946
Web: www.brightpoint.com
Phone: +1-317-7072355
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.50
High Stock Price Target: $3.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +50.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-98,040,000.00
Net Margins: -173.40%
Pretax Margin: -173.20%
Return on Equity: -73.02%
Return on Assets: -44.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.24
Quick Ratio: 1.26

Sales & Book Value

Annual Sales: $78.60 million
Price / Sales: 1.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.97 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 99,300,000
Free Float: 81,821,000
Market Cap: $99.11 million
Optionable: Not Optionable
Beta: 0.84

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Competitors

View All Competitors

CELL Stock Analysis - Frequently Asked Questions

Should I buy or sell Brightpoint stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brightpoint in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CELL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CELL, but not buy additional shares or sell existing shares.
View CELL analyst ratings or view top-rated stocks.
What is Brightpoint's stock price target for 2024?: 3 brokerages have issued 12-month target prices for Brightpoint's shares. Their CELL share price targets range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $1.50 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts price targets for CELL or view top-rated stocks among Wall Street analysts.
What other stocks do shareholders of Brightpoint own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Brightpoint investors own include (VMED) (VMED), TiVo (TIVO), RTX (RTX), Broadcom (AVGO).

This page (NASDAQ:CELL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Brightpoint (CELL) Stock Price, News & Analysis

Brightpoint MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Brightpoint Stock (NASDAQ:CELL)

CELL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Competitors

CELL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™